Select a medication above to begin.
Aduhelm (aducanumab-avwa)
aducanumab
Black Box Warnings .
Amyloid-Related Imaging Abnormalities (ARIA)
can cause ARIA w/ edema (ARIA-E) and ARIA w/ hemosiderin deposition (ARIA-H); incidence and timing vary; usually asymptomatic and occurs early in tx, though serious, life-threatening, or fatal events can occur; serious cerebral hemorrhage observed, incl. fatal; consider if focal neurologic deficits due to ARIA-E vs. ischemic stroke before admin. thrombolytic tx; apolipoprotein E epsilon 4 homozygotes have incr. ARIA incidence vs. heterozygotes and noncarriers; test for apolipoprotein E epsilon 4 status before tx start; before testing, discuss w/ pts ARIA risk across genotypes and implications of genetic testing results; inform pts they may receive tx w/o genotype testing, but it cannot be determined if they are apolipoprotein E epsilon 4 homozygotes at incr. ARIA risk; consider benefit vs. risk when deciding to initiate tx
Adult Dosing .
Dosage forms: INJ
Special Note
- [formulation clarification]
- Info: nonproprietary name = aducanumab-avwa
Alzheimer dz, mild cognitive impairment or mild dementia
- [10 mg/kg/dose IV q4wk]
- Start: 1 mg/kg/dose IV q4wk x2 doses, then 3 mg/kg/dose IV q4wk x2 doses, then 6 mg/kg/dose IV q4wk x2 doses, then 10 mg/kg/dose IV q4wk; Info: for pts w/ confirmed amyloid beta pathology; use ABW to calculate dose; if dose missed, resume at same dose ASAP; give doses >21 days apart; see pkg insert for dose interruptions based on brain MRI and sx severity in pts w/ amyloid-related imaging abnormalities
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.